Anti-Mouse FOXP3 – FITC

Anti-Mouse FOXP3 – FITC

Product No.: F406

[product_table name="All Top" skus="F1193"]

- -
- -
Clone
MF-14
Target
Foxp3
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Forkhead box protein P3, Scurfin, JM2, IPEX, Zinc finger protein JM2
Isotype
IgG1 κ
Applications
FC
,
ICC
,
ICFC
,
IF
,
IHC
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Mouse
Product Concentration
0.2 mg/ml
Formulation
This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (490 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC
Additional Applications Reported In Literature ?
IF,
ICFC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
MF-14 activity is directed against mouse FOXP3.
Antigen Distribution
FOXP3 is a unique marker of CD4+CD25+ regulatory T cells, distinguishing them from activated CD4+CD25 T cells.
Background
FOXP3 is a transcription factor1 required for development of CD4+CD25+ regulatory T cells (Treg) that does not affect CD4+CD25 T cell proliferation2. Treg cells expressing FOXP3 play a critical role in the maintenance of immune homeostasis and prevention of autoimmunity1. FOXP3 promotes the generation of Tregs, represses cytokine expression in primary CD4+ T cells, and suppresses the transcriptional activities of NFAT and NF-κB3. FOXP3 also inhibits basal activation of PKC-θ, IκB kinase β (IKKβ), and TNF-α stimulation of NF-κB. Depletion of FOXP3+CD4+ Treg cells and/or loss of function mutations of FOXP3 results in severe autoimmunity, allergy, immunopathology as well as cancer immunity1.

FOXP3 is predominantly expressed in CD25+CD4+ Tregs in the thymus and periphery2,4, and abundance increases upon in vitro activation of CD4+CD25+ Tregs2. Additionally, expression of FOXP3 in naïve T cells can convert these cells to a Treg phenotype4. FOXP3 is virtually undetectable in resting and activated CD4+CD25 T cells2.

FOXP3 represents a more specific marker for CD4+ Tregs than e.g., CD25, CD45RB, CTLA-4, and GITR which do not discriminate between Tregs and activated, effector, or memory T cells4.

Antigen Details

PubMed
NCBI Gene Bank ID
Research Area
Cancer
.
Immuno-Oncology
.
Immunology
.
Oncology
Flow Cytometry
ICC
ICFC
IF
IHC
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.